Baillie Gifford & Co. grew its position in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,705,756 shares of the company's stock after purchasing an additional 23,807 shares during the quarter. Baillie Gifford & Co. owned about 3.81% of BeiGene worth $831,979,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in shares of BeiGene by 63.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 2,280 shares of the company's stock valued at $357,000 after acquiring an additional 887 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of BeiGene during the 1st quarter worth approximately $209,000. Headlands Technologies LLC purchased a new stake in shares of BeiGene during the 1st quarter worth approximately $50,000. ProShare Advisors LLC increased its stake in shares of BeiGene by 8.1% during the 1st quarter. ProShare Advisors LLC now owns 2,902 shares of the company's stock worth $454,000 after purchasing an additional 217 shares during the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of BeiGene by 52.2% during the 1st quarter. Bleakley Financial Group LLC now owns 5,661 shares of the company's stock worth $885,000 after purchasing an additional 1,942 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently weighed in on BGNE. JMP Securities started coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a report on Tuesday, October 22nd. Finally, Citigroup boosted their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $246.21.
Check Out Our Latest Research Report on BGNE
BeiGene Trading Down 5.4 %
Shares of NASDAQ BGNE traded down $11.13 during midday trading on Tuesday, hitting $193.91. 141,961 shares of the company traded hands, compared to its average volume of 264,152. The firm has a market cap of $18.88 billion, a P/E ratio of -38.03 and a beta of 0.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $248.16. The stock has a 50-day moving average price of $212.67 and a 200 day moving average price of $181.34.
Insiders Place Their Bets
In related news, insider Titus B. Ball sold 137 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Titus B. Ball sold 137 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,070 shares of company stock worth $4,901,050. 7.43% of the stock is currently owned by company insiders.
BeiGene Profile
(
Free Report)
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
See Also
Before you consider BeiGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeiGene wasn't on the list.
While BeiGene currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
